

## Learner Notification

### MED Learning Group

### Weight No Longer: Addressing Overweight/Obesity as an Integral Part of Type 2 Diabetes Management

August 14, 2023 – August 14, 2024

Online

### Acknowledgement of Financial Commercial Support

Lilly

### Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

### Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion. Your chosen sessions must be viewed in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

### Joint Accreditation Statement



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MED Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

### Nurses (ANCC) Credit Designation

Amedco LLC designates this activity for a maximum of 1.00 ANCC contact hours.

### Objectives - After Attending This Program You Should Be Able To

1. Utilize guidelines and clinical data supporting a weight-centric approach to the treatment of patients with type 2 diabetes.
2. Select pharmacological agents that facilitate both weight management and glycemic control.
3. Implement shared decision-making strategies to help patients with type 2 diabetes select and follow through with informed options for weight loss.

### Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5)

All individuals in a position to control the content of CE are listed below.

First Name	Last Name	Commercial Interest: Relationship
Russie	Allen	NA
Felecia	Beachum	NA
Naomi	De Brito	NA
Matthew	Frese	NA
Christina	Gallo	NA
Davida F.	Kruger	Abbott, CeQur, Lilly, Mannkind, Medtronic, Mobular Medical, Novo Nordisk, Sanofi: Consultant, Dexcom, CeQur, Lilly, Novo, Sanofi, Xeris: Speakers Bureau, Abbott, Beta Bionics, Novo: Contracted Research, Pendulum: Stock Shareholder
Cindy	Lampner	NA
Kim	Pfotenhauer	NA
Jo	Shultz	NA
Lauren	Welch	NA

Questions? Email [Certificate@AmedcoEmail.com](mailto:Certificate@AmedcoEmail.com)